Results of subconjunctival 5-fluorouracil in the management of bleb failure: A case series

Volume: 54 Number: 3 September 1, 2015
  • İhsan Yılmaz
  • Ebru Demet Aygıt
  • Sevil Karaman Erdur
  • Ahmet Demirok
Ege Journal of Medicine Cover
Ege Journal of Medicine
PDF Download
EN TR

Results of subconjunctival 5-fluorouracil in the management of bleb failure: A case series

Abstract

Aim: To evaluate the efficacy of 5-Fluorouracil (5-FU) injections in eyes with bleb failure and uncontrolled intraocular pressure (IOP) after trabeculectomy. Materials and Methods: Fifteen eyes of 15 patients (6 female, 9 male) were included in this retrospective study. All patients had trabeculectomy surgery for the treatment of primary open angle glaucoma. During the first year follow-ups, cases with IOP higher than 21 mmHg and ineffective blebs were considered as bleb failure. We used 5-FU subconjunctival injections, in the same concentration (5 mg) but in different numbers, to treat the bleb failure and lower the IOP. The efficacy of the treatment was evaluated. Results: The mean age was 59.3±12.4 years (range 43-74 years). The mean 5-FU injection count was 5.27±1.58 injections (range 2-7). The mean IOP was reduced to 17.07±7.10 mmHg after treatment. There was a statistically significant difference in IOP levels before and after the injections (p

Keywords

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

İhsan Yılmaz

Ebru Demet Aygıt

Sevil Karaman Erdur

Ahmet Demirok

Publication Date

September 1, 2015

Submission Date

September 1, 2015

Acceptance Date

-

Published in Issue

Year 2015 Volume: 54 Number: 3

DOI

https://doi.org/10.19161/etd.344128

IZ

https://izlik.org/JA97SM86BF

Cite

RIS / Bibtex
Vancouver
1.İhsan Yılmaz, Ebru Demet Aygıt, Sevil Karaman Erdur, Ahmet Demirok. Bleb yetersizliğinin tedavisinde subkonjonktival 5-fluorourasil kullanımının sonuçları: Olgu serisi. EJM. 2015 Sep. 1;54(3):111-3. doi:10.19161/etd.344128

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.